World-renowned scientists leverage bioelectronics materials and devices to treat chronic disease.
Aix-en-Provence, FRANCE, and Toronto, CANADA, August 1, 2017. Bioelectronic medicine company Panaxium SAS today announced that internationally-renowned scholars Professor George Malliaras, the Prince Philip Professor of Technology at the University of Cambridge, and Dr. Róisín M. Owens, Group Leader for the esteemed BioElectronic Systems Technologies (B.E.S.T.) Group at the University of Cambridge, will join the company as Principal Scientific Advisors.
Bioelectronic medicine is an emerging scientific field that aims to tackle many debilitating and degenerative medical conditions and injuries by leveraging the newest bioelectronics and building imperceptible devices at the microscale dimensions of individual cells. There is significant potential to treat a wide range of diseases such as Traumatic Brain Injuries, Parkinson’s, Alzheimer’s, and even peripheral nerve damage.
Professor Malliaras’ research is focused on the design and validation of cutaneous devices to interface with the brain, with the aim of understanding and treating neurological disorders, as well as the development of electronic devices and circuits that mimic some of the computational features of the human brain. Prior to Cambridge, Professor Malliaras founded and served as Department Head for the Department of Bioelectronics at L’École Nationale Supérieure des Mines de Saint-Étienne (France) and previously served as the Lester B. Knight Director of the Cornell NanoScale Science & Technology Facility (CNF) at Cornell University (New York).
Dr. Owens’ BioElectronic Systems Technologies group’s core expertise is in the generation of biomimetic biological models with integrated electronic devices for monitoring or modulation. Her significant expertise is in working with organic electronics, specifically in conducting polymers that have been shown to be particularly apt at interfacing with biological systems. Dr. Owens’ current research is centered on harnessing the power of engineering for developing in vitro biological models, with a specific interest in studying the gut-brain-microbiome axis.
Dr. Brad Schmidt, CEO of Panaxium, says of the Malliaras and Owens appointment, “We are thrilled that Professor Malliaras and Professor Owens have joined Panaxium as our Principal Scientific Advisors. Their vanguard contributions to the field of bioelectronic medicine are not only extraordinary but also long-lasting. They share the belief that the vast potential of this field will be unlocked by imagining new therapeutic devices from the foundational level, which starts with fundamental understanding of new enabling materials. We are truly excited to work with Professor Malliaras and Dr. Owens to build the Panaxium labs and see this long-held vision be realized through the commercialization of bioelectronic medicine treatments.”
Founded in 2016, Panaxium is a new and rapidly-growing bioelectronic medicine company aiming to fundamentally change the way disease is treated. The company is comprised of a multidisciplinary team of internationally-renowned scientists, including world experts in organic bioelectronics and leaders in the fields of chemistry, materials science, electrical engineering, systems design, electronic engineering, data science, biology, biochemistry, and nanotechnology. Together they are working to solve some of the most difficult and important problems in medicine.
For further information, please visit http://www.panaxium.com